Effects of 5-azacytidine on transfer RNA modification: Comparative study on normal and malignant tissues

Leejane Lu, G. H. Chiang, K. Randerath

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In general, the treatment of animals with 5-azacytidine (1-β-D-ribofuranosyl-4-amino-s-triazine-2 (1H)-one) was found to lead to a specific reduction of the 5-methylcytidine (m5C) content of tRNA in tissues, e.g. liver, hepatoma, mammary tumor, and spleen; however, the effect of the drug on post-transcriptional tRNA modification was more general in lymp nodes and in leukemic cells. Many base modifications of L 1210 cell tRNA were inhibited, with m5C and dihydrouridine (hU) being affected the most. A positive correlation existed between the extent of inhibition of the formation of m5C and other modified nucleosides and the antitumor activity of the drug.

Original languageEnglish (US)
Pages (from-to)577-584
Number of pages8
JournalLife Sciences
Volume27
Issue number7
DOIs
StatePublished - 1980
Externally publishedYes

Fingerprint

Azacitidine
Transfer RNA
Tissue
Triazines
Nucleosides
Pharmaceutical Preparations
Liver
Antineoplastic Agents
Tumors
Hepatocellular Carcinoma
Animals
Spleen
Breast Neoplasms

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of 5-azacytidine on transfer RNA modification : Comparative study on normal and malignant tissues. / Lu, Leejane; Chiang, G. H.; Randerath, K.

In: Life Sciences, Vol. 27, No. 7, 1980, p. 577-584.

Research output: Contribution to journalArticle

@article{527c47e57da94cd68b52aa96d6db6b8f,
title = "Effects of 5-azacytidine on transfer RNA modification: Comparative study on normal and malignant tissues",
abstract = "In general, the treatment of animals with 5-azacytidine (1-β-D-ribofuranosyl-4-amino-s-triazine-2 (1H)-one) was found to lead to a specific reduction of the 5-methylcytidine (m5C) content of tRNA in tissues, e.g. liver, hepatoma, mammary tumor, and spleen; however, the effect of the drug on post-transcriptional tRNA modification was more general in lymp nodes and in leukemic cells. Many base modifications of L 1210 cell tRNA were inhibited, with m5C and dihydrouridine (hU) being affected the most. A positive correlation existed between the extent of inhibition of the formation of m5C and other modified nucleosides and the antitumor activity of the drug.",
author = "Leejane Lu and Chiang, {G. H.} and K. Randerath",
year = "1980",
doi = "10.1016/0024-3205(80)90307-0",
language = "English (US)",
volume = "27",
pages = "577--584",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Effects of 5-azacytidine on transfer RNA modification

T2 - Comparative study on normal and malignant tissues

AU - Lu, Leejane

AU - Chiang, G. H.

AU - Randerath, K.

PY - 1980

Y1 - 1980

N2 - In general, the treatment of animals with 5-azacytidine (1-β-D-ribofuranosyl-4-amino-s-triazine-2 (1H)-one) was found to lead to a specific reduction of the 5-methylcytidine (m5C) content of tRNA in tissues, e.g. liver, hepatoma, mammary tumor, and spleen; however, the effect of the drug on post-transcriptional tRNA modification was more general in lymp nodes and in leukemic cells. Many base modifications of L 1210 cell tRNA were inhibited, with m5C and dihydrouridine (hU) being affected the most. A positive correlation existed between the extent of inhibition of the formation of m5C and other modified nucleosides and the antitumor activity of the drug.

AB - In general, the treatment of animals with 5-azacytidine (1-β-D-ribofuranosyl-4-amino-s-triazine-2 (1H)-one) was found to lead to a specific reduction of the 5-methylcytidine (m5C) content of tRNA in tissues, e.g. liver, hepatoma, mammary tumor, and spleen; however, the effect of the drug on post-transcriptional tRNA modification was more general in lymp nodes and in leukemic cells. Many base modifications of L 1210 cell tRNA were inhibited, with m5C and dihydrouridine (hU) being affected the most. A positive correlation existed between the extent of inhibition of the formation of m5C and other modified nucleosides and the antitumor activity of the drug.

UR - http://www.scopus.com/inward/record.url?scp=0019194933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019194933&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(80)90307-0

DO - 10.1016/0024-3205(80)90307-0

M3 - Article

C2 - 6158642

AN - SCOPUS:0019194933

VL - 27

SP - 577

EP - 584

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 7

ER -